BioMarin Pharmaceutical (BMRN) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Strategic and operational updates

• Significant changes made to strategy, structure, pipeline, and portfolio since December 2023, resulting in strong execution and 16% revenue growth in the last quarter.

• Positive phase I results for BMN 333, a long-acting CNP, led to advancement into a phase II/III program, with regulatory alignment from the FDA.

• InnoSIGN acquisition completed in one quarter, adding a first-in-disease ENPP1 asset with peak sales potential of $500–600 million and first pivotal data expected in 2026.

• VOXZOGO launched in 51 countries, with plans to reach 60 by 2027; 75% of revenue is from outside the U.S., and further growth expected from new indications and market penetration.

• PALYNZIQ showed 21% growth in H1, with adolescent data supporting a potential 10% increase in patient population and continued expansion in the severe PKU segment.

Market and competitive landscape

• China is seen as a rising force in biotech, but activity in genetically defined conditions remains limited; U.S. maintains leadership in this area.

• AI is being leveraged across R&D, regulatory, manufacturing, and commercial functions, with a fast-follower strategy until 2027 and ambitions for leadership thereafter.

• Competitive advantage in rare diseases comes from a broad global footprint and early diagnosis/treatment, especially for VOXZOGO, with limited risk from new entrants due to established presence and data requirements.

• New PKU competitor expected to impact KUVAN more than PALYNZIQ, as patient segments differ significantly.

Regulatory and macro environment

• Positive engagement with the FDA, especially in rare diseases, with no current staffing issues and clear alignment on pivotal programs.

• Tariff risks are mitigated by a balanced U.S./EU manufacturing footprint and revenue split; MFN in Medicaid is a concern due to potential disincentives for rare disease innovation.

• Ongoing monitoring of regulatory and trade developments, with hedges in place to manage potential impacts.